Unicycive Therapeutics Stock Today
| UNCY Stock | USD 0.69 0.01 1.47% |
Performance19 of 100
| Odds Of DistressLess than 17
|
Unicycive Therapeutics is trading at 0.69 as of the 30th of November 2024; that is 1.47 percent increase since the beginning of the trading day. The stock's open price was 0.68. Unicycive Therapeutics has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a solid performance during the last 90 days. Equity ratings for Unicycive Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of July 2021 | Category Healthcare | Classification Health Care |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 103.8 M outstanding shares of which 1.26 M shares are at this time shorted by private and institutional investors with about 0.74 trading days to cover. More on Unicycive Therapeutics
Moving together with Unicycive Stock
| 0.7 | VTRS | Viatris | PairCorr |
| 0.76 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.62 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.73 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Unicycive Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Unicycive Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsUnicycive Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Unicycive Therapeutics' financial leverage. It provides some insight into what part of Unicycive Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unicycive Therapeutics (UNCY) is traded on NASDAQ Exchange in USA. It is located in 4300 El Camino Real, Los Altos, CA, United States, 94022 and employs 14 people. Unicycive Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 70.36 M. Unicycive Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 103.8 M outstanding shares of which 1.26 M shares are at this time shorted by private and institutional investors with about 0.74 trading days to cover.
Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Unicycive Therapeutics Probability Of Bankruptcy
Ownership AllocationUnicycive Therapeutics shows a total of 103.8 Million outstanding shares. 30% of Unicycive Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Unicycive Ownership Details
Unicycive Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bleakley Financial Group Llc | 2024-09-30 | 80 K | |
| Xtx Topco Ltd | 2024-09-30 | 70.8 K | |
| Blackrock Inc | 2024-06-30 | 51.8 K | |
| State Street Corp | 2024-06-30 | 43.9 K | |
| Northern Trust Corp | 2024-09-30 | 24 K | |
| Captrust Financial Advisors | 2024-06-30 | 18.8 K | |
| Tower Research Capital Llc | 2024-06-30 | 18.5 K | |
| Tandem Capital Management Corp | 2024-09-30 | 15.5 K | |
| Virtu Financial Llc | 2024-06-30 | 11.1 K | |
| Octagon Capital Advisors Lp | 2024-09-30 | 8.6 M | |
| Logos Global Management Lp | 2024-06-30 | 6.9 M |
Unicycive Therapeutics Historical Income Statement
Unicycive Stock Against Markets
Unicycive Therapeutics Corporate Management
| MPA MD | Chairman, Founder | Profile | |
| Pramod Gupta | Executive Operations | Profile | |
| John CPA | Chief Officer | Profile | |
| Douglas MBA | Executive Strategy | Profile |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.